Mechanism of Splicing Regulation of Spinal Muscular Atrophy Genes
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Spinal muscular atrophy (SMA) is one of the major genetic disorders associated with infant mortality. More than 90% cases of SMA result from deletions or mutations of Survival Motor Neuron 1 (SMN1) gene. SMN2, a nearly identical copy of SMN1, does not compensate for the loss of SMN1 due to predominant skipping of exon 7. However, correction of SMN2 exon 7 splicing has proven to confer therapeutic benefits in SMA patients. The only approved drug for SMA is an antisense oligonucleotide (Spinraza™/Nusinersen), which corrects SMN2 exon 7 splicing by blocking intronic splicing silencer N1 (ISS-N1) located immediately downstream of exon 7. ISS-N1 is a complex regulatory element encompassing overlapping negative motifs and sequestering a cryptic splice site. More than 40 protein factors have been implicated in the regulation of SMN exon 7 splicing. There is evidence to support that multiple exons of SMN are alternatively spliced during oxidative stress, which is associated with a growing number of pathological conditions. Here, we provide the most up to date account of the mechanism of splicing regulation of the SMN genes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Collectively, evidence from patient-derived cells and SMA vertebrate models demonstrates that SMN deficiency broadly impairs snRNP assembly, resulting in widespread splicing abnormalities—including exon skipping, intron retention, and altered splice site selection—in transcripts essential for neuronal function and survival [20, 21].”
From Widespread intron retention and exon skipping characterise alternative splicing changes in a C. elegans model of spinal muscular atrophy (2026) · cites this paper as [21]
In the citing paper
“These findings support a unifying model in which global splicing dysfunction represents a central pathogenic mechanism in SMA [18, 21].”
From Widespread intron retention and exon skipping characterise alternative splicing changes in a C. elegans model of spinal muscular atrophy (2026) · cites this paper as [21]
In the citing paper
“Widespread, tissue-specific reductions in snRNP abundance, along with disruption of both major and minor spliceosome components, have been reported in human SMA patient samples and animal models.”
From Widespread intron retention and exon skipping characterise alternative splicing changes in a C. elegans model of spinal muscular atrophy (2026) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Spliceosome: Design Principles of a Dynamic RNP Machine
Wahl, M. C., Will, C. L., & Lührmann, R. (2009) · Cell · doi:10.1016/j.cell.2009.02.009 · Cited by 2,665
Mechanisms and Regulation of Alternative Pre-mRNA Splicing
Lee, Y., & Rio, D. C. (2015) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-034316 · Cited by 1,291 · cited 2×
“Interpreting the consequences of a splicing-associated mutation remains a puzzle, since a single mutation can cause at least one of the following changes: loss of a positive element, gain of a negative element, change of a structural context, and nonsense-mediated decay (NMD) due to creation of an in-frame premature t…”
BackgroundContext-dependent control of alternative splicing by RNA-binding proteins
Fu, X.-D., & Ares, M. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3778 · Cited by 1,044 · cited 1×
“Rules of splicing are quite flexible and are heavily influenced by the relative abundance of various splicing factors in different tissues [8].”
BackgroundRaj, B., & Blencowe, B. J. (2015) · Neuron · doi:10.1016/j.neuron.2015.05.004 · Cited by 475
Huelga, S. C., Vu, A. Q., Arnold, J. D., Liang, T. Y., Liu, P. P., Yan, B. Y., Donohue, J. P., Shiue, L., Hoon, S., Brenner, S., et al. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.02.001 · Cited by 470
Cited by
Advances in oligonucleotide drug delivery
Roberts, T. C., Langer, R., & Wood, M. J. A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0075-7 · Cited by 2,027
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 828
Alternative splicing and cancer: a systematic review
Zhang, Y., Qian, J., Gu, C., & Yang, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00486-7 · Cited by 497
Mercuri, E., Sumner, C. J., Muntoni, F., Darras, B. T., & Finkel, R. S. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00380-8 · Cited by 430
Wirth, B., Karakaya, M., Kye, M. J., & Mendoza-Ferreira, N. (2020) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-102319-103602 · Cited by 255
Metadata
- Authors
- Singh, R. N., & Singh, N. N.
- Venue
- Advances in Neurobiology
- Publisher
- Springer International Publishing
- Published
- 2018
- Volume
- 20
- Pages
- 31-61
- ISSN
- 2190-5215 (ISSN-L)
- 2190-5223
- OpenAlex
- W2809192712
- Cited by
- 142
- References
- 5
- FWCI
- 29.44
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.